Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 426 - 450 of 14724 in total

Grepafloxacin

Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Approved
Investigational
Withdrawn
Matched Description: … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections ... QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and …

Phenformin

A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Approved
Investigational
Withdrawn
Matched Description: … A biguanide hypoglycemic agent with actions and uses similar to those of metformin. …
Matched Categories: … Alimentary Tract and Metabolism ... phenformin and sulfonylureas …

Osimertinib

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Crotalus adamanteus antivenin

Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 . The eastern diamondback...
Approved
Experimental
Matched Description: … The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F116]. ... Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide ... isolating the antivenin of interest through fractionation and chromatography techniques. …

Vildagliptin

Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl ... [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment ... Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and vildagliptin …

Clozapine

Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical". . This low affinity to dopamine receptors results in fewer extrapyramidal side effects,...
Approved
Matched Description: … Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. ... [A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the ... side effects, notably gastrointestinal hypomotility and orthostatic hypotension. …
Matched Categories: … Antidepressive Agents ... Diazepines, Oxazepines, Thiazepines and Oxepines …

Latanoprost

Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use...
Approved
Investigational
Matched Description: … It was initially approved by the FDA in 1998. ... [A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse …
Matched Mixtures name: … Latanoprost and Timolol Ophthalmic Solution ... Latanoprost and Timolol STADA 50mcg/ml + 5mg/ml Eye drops ... LATANOPROST 0.05 MG/ML AND TIMOLOL 5 MG/ML SANDOZ EYE DROPS …
Matched Categories: … latanoprost and netarsudil ... Antiglaucoma Preparations and Miotics …

Clodronic acid

Clodronic acid is a first generation bisphosphonate similar to etidronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate zoledronic acid, ibandronic acid,...
Approved
Investigational
Vet approved
Matched Description: … [A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910] ... Clodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid] ... A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and …
Matched Categories: … Drugs Affecting Bone Structure and Mineralization …

Propiomazine

Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds...
Approved
Matched Description: … Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of ... H1, muscarinic, and serotonin type 2 (5-HT2) receptors. ... schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. …
Matched Categories: … Antidepressive Agents ... Hypnotics and Sedatives …

Bepotastine

Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. ... Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus ... in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand …

Tacrolimus

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis...
Approved
Investigational
Matched Description: … drug whose main use is after organ transplant to reduce the activity of the patient's immune system and ... the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and ... This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL …
Matched Categories: … Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Topiramate

Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy...
Approved
Matched Description: … Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. ... [A175249] It was initially approved by the FDA in 1996. ... In 2004, topiramate was approved for the prevention of migraine in adults. …
Matched Categories: … Alimentary Tract and Metabolism ... phentermine and topiramate …

Avalglucosidase alfa

Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … [L39205] The EMA approved the drug on June 24, 2022.[L42720] ... [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of ... [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Nedocromil

A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Matched Description: … are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and …
Matched Categories: … Decongestants and Antiallergics …

Moxonidine

Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown...
Approved
Investigational
Matched Description: … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild ... suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and …
Matched Categories: … moxonidine and diuretics …

Pralsetinib

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced ... Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Estazolam

A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Approved
Illicit
Matched Description: … A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Oritavancin

Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Description: … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive ... [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in ... [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Penbutolol

Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker ... degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. ... Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third …
Matched Categories: … Antidepressive Agents ... penbutolol and other diuretics …

Thonzonium

Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Description: … Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular ... debris and exudate, thereby promoting tissue contact of the administered medication. …

Dostarlimab

Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … [L33340] A companion diagnostic device - the VENTANA MMR RxDx Panel - was also approved alongside this ... those of the skin, lung, kidneys, and liver. ... [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Cobimetinib

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Icodextrin

Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport...
Approved
Investigational
Matched Description: … It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal …

Sulconazole

Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream ... and solution. ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial …
Matched Categories: … Imidazole and Triazole Derivatives …
Displaying drugs 426 - 450 of 14724 in total